HALF-YEARLY REPORT ON THE LIQUIDITY CONTRACT WITH INVEST SECURITIES

Berlin, Germany, January 20, 2023, 06.00 p.m. CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that pursuant to the liquidity contract entrusted to Invest Securities by *TME Pharma N.V*. the assets outlined below appeared on the liquidity account. During the reporting period the company changed its name from *NOXXON Pharma* to *TME Pharma* (July 15, 2022), and effected a share consolidation such that every 100 shares with a nominal value of 1 eurocent each were consolidated and converted into 1 new share with a nominal value of 1 euro (July 27, 2022). Both processes are being reflected in this half-yearly report.

The following assets appeared on the liquidity account as of December 31, 2022:

- Number of shares: 13,992
- Cash balance of the liquidity account: €11,622.12

For the period July 28, 2022 – December 31, 2022:

- Total number of shares bought: 81,080
  representing an amount of: €217,453.70
  representing total transactions of: 1,222

- Total number of shares sold: 67,779
  representing an amount of: €185,844.42
  representing total transactions of: 1,519

The company made an additional payment of €15,000.00 on November 23, 2022, into the liquidity account in order to improve the balance and maintain the liquidity contract. For more detailed information for the period of July 28, 2022 – December 31, 2022, please see annex A of this press release.

The following assets appeared on the liquidity account as of July 27, 2022:

- Number of shares: 691 (equating to 69,192 before the share consolidation)
- Cash balance of the liquidity account: €28,231.41

For the period July 01, 2022 – July 27, 2022:

- Total number of shares bought: 47,517
  representing an amount of: €2,173.69
  representing total transactions of: 33

- Total number of shares sold: 64,518
  representing an amount of: €3,260.45
  representing total transactions of: 42

As a reminder, as of June 30, 2022, the following assets appeared on the liquidity account:

- Number of shares: 86,193
- Cash balance of the liquidity account: €27,144.62

For more detailed information for the period of July 01, 2022 – July 27, 2022, please see annex B of this press release.

For more information, please contact:

TME Pharma N.V.
Aram Mangasarian, Ph.D., CEO
Tel. +49 (0) 30 726247 0
investors@tmepharma.com

Investor and Media Relations:

LifeSci Advisors
Guillaume van Renterghem
Tel. +41 (0) 76 735 01 31
gvanrenterghem@lifesciadvisors.com

NewCap
Arthur Rouillé
Tel. +33 (0) 1 44 71 00 15
arouille@newcap.fr

About TME Pharma

TME Pharma is a clinical-stage company focused on developing novel therapies for treatment of the most aggressive cancers. The company's oncology-focused pipeline is designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. By neutralizing chemokines in the TME, *TME Pharma's* approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. In the GLORIA clinical trial, *TME Pharma* is studying its lead drug candidate NOX-A12 in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. *TME Pharma* has delivered top-line data from the NOX-A12 three dose-escalation cohorts combined with radiotherapy of the GLORIA clinical trial, observing consistent tumor reductions and objective tumor responses. Additionally, GLORIA expansion arms evaluate safety and efficacy of NOX-A12 in other combinations where the interim results from the triple combination of NOX-A12, radiotherapy and bevacizumab suggest even deeper and more durable responses. NOX-A12 in combination with radiotherapy has received orphan drug designation for glioblastoma in the United

States and glioma in Europe. *TME Pharma* has delivered final top-line data with encouraging overall survival and safety profile from its NOX-A12 combination trial with Keytruda® in metastatic colorectal and pancreatic cancer patients, which was published in the Journal for ImmunoTherapy of Cancer in October 2021. The company has entered in its second collaboration with MSD/Merck for its Phase 2 study, OPTIMUS, to further evaluate safety and efficacy of NOX-A12 in combination with Merck's Keytruda® and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The design of the trial is in discussion with regulatory authorities in the United States and Europe. The company's second clinical-stage drug candidate, NOX-E36, is designed to target the innate immune system. *TME Pharma* is considering several solid tumors for further clinical development. Further information can be found at: www.tmepharma.com.

Visit *TME Pharma* on LinkedIn and Twitter.

About the GLORIA Study

GLORIA (NCT04121455) is *TME Pharma's* dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates safety and efficacy of NOX-A12 three additional arms combining NOX-A12 with: A. radiotherapy in patients with complete tumor resection; B. radiotherapy and bevacizumab; and C. radiotherapy and pembrolizumab.

About the OPTIMUS Study

OPTIMUS (NCT04901741) is *TME Pharma's* planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.

Disclaimer

Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain "forward-looking statements." Forward-looking statements are based on *TME Pharma's* current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and *TME Pharma's* ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made as of this date, and *TME Pharma* undertakes no duty to update such information except as required under applicable law.